Anti-CD19 antibody [MB19-1] (PE/Cy5.5 ®) (ab25384)


  • Product nameAnti-CD19 antibody [MB19-1] (PE/Cy5.5 ®)
    See all CD19 primary antibodies
  • Description
    Mouse monoclonal [MB19-1] to CD19 (PE/Cy5.5 ®)
  • ConjugationPE/Cy5.5 ®. Ex: 496nm, Em: 690nm
  • SpecificityCD19 B cell differentiation antigen, Mr 95 kDa.
  • Tested applicationsSuitable for: Flow Cyt, IPmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    CD19+ mouse pre-B cell line, 300.19

  • Positive control
    • Mature B cells. All splenic and peritoneal IgM+ cells of B1 and B2 lineages.
  • General notesTo ensure consistency of performance, each batch of monoclonal antibody is tested by flow cytometry to conform to characteristics of a standard reference reagent. This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.



Our Abpromise guarantee covers the use of ab25384 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
  • Application notesFlow Cyt: Use up to 0.2µg to label 106 cells.
    IP: Use at an assay dependent dilution.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
    • Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    • Sequence similaritiesContains 2 Ig-like C2-type (immunoglobulin-like) domains.
    • Post-translational
      Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Antibody deficiency due to defect in CD19, included antibody
      • AW495831 antibody
      • B lymphocyte antigen CD19 antibody
      • B lymphocyte surface antigen B4 antibody
      • B-lymphocyte antigen CD19 antibody
      • B-lymphocyte surface antigen B4 antibody
      • B4 antibody
      • CD19 antibody
      • CD19 antigen antibody
      • CD19 molecule antibody
      • Cd19 protein antibody
      • CD19_HUMAN antibody
      • CVID3 antibody
      • Differentiation antigen CD19 antibody
      • Leu 12 antibody
      • Leu-12 antibody
      • Leu12 antibody
      • MGC109570 antibody
      • MGC12802 antibody
      • T-cell surface antigen Leu-12 antibody
      see all

    References for Anti-CD19 antibody [MB19-1] (PE/Cy5.5 ®) (ab25384)

    ab25384 has not yet been referenced specifically in any publications.

    Product Wall

    Application Flow Cytometry
    Sample Dog Cell (Whole blood)
    Permeabilization No
    Gating Strategy Lymphocytes
    Specification Whole blood
    Preparation Cell harvesting/tissue preparation method: Whole blood washed in PBS and lysed
    Sample buffer: PBS

    Anushka George

    Verified customer

    Submitted Mar 15 2016

    Thank you for contacting us.

    Please check the following antibodies;

    I hope this inform...

    Read More